A Retrospective Cohort Analysis of SMARCA4-Deficient Lung Cancer

计划入组 221 人 · 首次发布于 2025 年 8 月 13 日

Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

计划入组 86 人 · 首次发布于 2022 年 3 月 18 日

IRCI Gynae Sarcomas, High Grade Uterine Sarcoma

计划入组 58 人 · 首次发布于 2013 年 11 月 8 日

Sarcoma(Diakonos)

Sarcoma(Arpeggio Biosciences)

Ewing sarcoma program

Italian Sarcoma Group

Italy

Sarcoma Oncology Research Center LLC

United States

Sarc

United States

Hanmi Pharmaceutical's Dual EZH1/2 Inhibitor Shows Promising Antitumor Activity in Phase 1 Trial

Prelude Therapeutics' PRT3789 Shows Promise in SMARCA4-Mutated Cancers

Novel Synthetic Lethal Approaches Show Promise in Targeting MTAP and SMARCA4 Mutations in Lung Cancer